arGEN-X will generate mAb candidates against undisclosed targets from Eli Lilly

Eli Lilly and Co.

U.S. / Large-Cap Biopharma (>=$50 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

argenx S.E.

the Netherlands / Private Biopharma

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced